Compare Natera Inc. Common Stock (NTRA) vs Opendoor Technologies Inc (OPEN) Price & Performance

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

Opendoor (OPEN) trades at $1.99, down 4.78% on the day, reflecting persistent bearish sentiment amid a challenging housing market. The stock shows oversold technical signals with an RSI near 21, while fundamentals reveal steep losses with a net income margin of -46.74% in 2025 and negative ROE of -196.89%. Recent news highlights expansion into mortgages across 35-40 states by end-2026 to drive growth, but earnings misses in Q1 and Q2 2026 underscore execution risks. Cash flow improved in 2025 with net positive $538M, yet 2026 projections show renewed outflows.

The outlook remains cautious; analyst consensus is mixed with 65% hold ratings, but a $4.92 price target implies significant upside if turnaround succeeds. Key risks include interest rate sensitivity, high debt levels, and prolonged profitability challenges. Revenue declines from $15.6B in 2022 to $4.4B in 2025 highlight operational headwinds, making recovery dependent on housing market stabilization and cost controls.